Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Passes 'Minibus' Appropriations Bill Increasing NIH Funds And Directing CMS Program Funding

Executive Summary

A "minibus" appropriations bill approved by the Senate on Aug. 24 would increase National Institutes of Health funding by 5.4% to $2bn in 2019, and bolster several programs of interest to industry at NIH and at the Centers for Medicare and Medicaid Services.

You may also be interested in...



US House Would Boost NIH Spending By $2Bn, Support Precision Medicine, BRAIN Initiative, Cybersecurity Funds

The US National Institutes of Health would get a 5% raise of $2bn under a 2020 budget increase to $41.1bn, spending that would go to boost precision medicine research, the BRAIN Initiative, Cancer Moonshot, cybersecurity and other important programs.

Medtech Tools To Help Address Opioid Crisis Face Reimbursement Challenges

A wide variety of devices that could either serve as pain-relief substitutes for opioids, help manage opioid addictions or tackle distribution issues with the overly prescribed medications are facing reimbursement challenges at the US Centers for Medicare and Medicaid Services.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT123199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel